Doctor profile · Federal record
Dr. Enieni Okoya, APRN
Psychiatric/Mental Health Nurse Practitioner · Norman, OK
- NPI 1477751196
- 19 yrs on file
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
900 E. Main Street,, Red Rock Behavioral Health Services Building 52-100
Norman, OK 73071
(405) 307-4800 - Mailing address
-
2804 Pecan Vly
Norman, OK 730691202
Credentials & registration
- NPI registered
- July 2007 — 19 yrs on file
- Profile last updated
- April 19, 2017
- Specialty taxonomy
- 363LP0808X — NUCC code
- State license (1)
- Oklahoma #91263
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1477751196. Last verified May 11, 2026.Open Payments
Industry payments received
All-time total
$1,335
Transactions
37
Manufacturers
10
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | 12 | $464.04 | |
| ABBVIE INC. | 9 | $261.83 | |
| Teva Pharmaceuticals USA, Inc. | 4 | $253.22 | |
| ACADIA Pharmaceuticals Inc | 1 | $113.68 | |
| Otsuka America Pharmaceutical, Inc. | 4 | $79.72 | |
| Lundbeck LLC | 3 | $73.40 | |
| Alkermes, Inc. | 1 | $27.02 | |
| Gilead Sciences, Inc. | 1 | $25.75 | |
| Indivior Inc. | 1 | $21.67 | |
| BioXcel Therapeutics, Inc. | 1 | $15.06 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
47
Patients
45
Total drug cost
$576
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Olanzapine | Generic | 18 | 16 | $316 |
| Trazodone Hcl | Generic | 16 | 16 | $130 |
| Hydroxyzine Pamoate | Generic | 13 | 13 | $130 |
Frequently asked questions
What is Dr. Enieni Okoya's medical specialty?
Dr. Enieni Okoya practices Psychiatric/Mental Health Nurse Practitioner in Norman, OK.
Where does Dr. Enieni Okoya practice?
Dr. Enieni Okoya practices at 900 E. Main Street,, Norman, OK 73071. Office phone: 4053074800.
What is Dr. Enieni Okoya's NPI?
Dr. Enieni Okoya's National Provider Identifier (NPI) is 1477751196, issued by NPPES.